Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Study to Assess the Effect of Avastin (Bevacizumab) Combined With First Line Paclitaxel-carboplatin or Second Line Tarceva (Erlotinib) on Progression-free Survival in Non-squamous Non-small Cell Lung Cancer Patients With Asymptomatic Untreated Brain Metastasis

NCT00800202 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT00800202
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00800202 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Study to Assess the Effect of Avastin (Bevacizumab) Combined With First Line Paclitaxel-carboplatin or Second Line Tarceva (Erlotinib) on Progression-free Survival in Non-squamous Non-small Cell Lung Cancer Patients With Asymptomatic Untreated Brain Metastasis
Lead sponsor
Hoffmann-La Roche
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2009
Completion date
October 31, 2012
Enrollment
91 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer